Ligand Pharmaceuticals has been on a powerful run in recent years, which naturally puts the focus on whether the current share price lines up with the cash the business can generate. With the stock now trading around US$311.73, the key issue is how that market value compares to what its cash flows may be worth on a Discounted Cash Flow (DCF) basis.
- Over the past 3 years the stock has returned roughly 5x, so a lot of optimism is already embedded in the share price and the question is how that lines up with its cash flow profile.
- Fresh analyst enthusiasm, including a higher price target tied to improved revenue and profit trends, suggests expectations for future cash generation may have shifted upward and could affect what investors are willing to pay for those streams.
- What if you looked at Ligand Pharmaceuticals through its earnings instead? See why Ligand Pharmaceuticals's 31.5x P/E tells a different valuation story.
The issue now is whether Ligand Pharmaceuticals' current valuation is adequately supported by its cash flows when assessed using a Discounted Cash Flow (DCF) view.
If you want a broader watchlist of companies while you assess whether Ligand Pharmaceuticals' current share price is justified by its cash flows, a focused starting point is 29 high quality undervalued stocks.
Is Ligand Pharmaceuticals a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) approach here looks at the cash Ligand Pharmaceuticals could return to shareholders over time. On this model, the business generated last twelve month free cash flow of about $130.1 million and the projections assume that cash figure grows, with estimated annual free cash flows moving higher over the coming decade rather than shrinking.
The DCF output suggests Ligand Pharmaceuticals' projected cash generation implies an intrinsic worth meaningfully above the current share price of $311.73. Because Bank of America Securities recently lifted its price target after stronger revenue and profit, the positive cash flow profile in this model is consistent with that more upbeat view of the business. Find out what Ligand Pharmaceuticals could be worth using our Discounted Cash Flow (DCF) estimate.
The Ligand Pharmaceuticals Narrative: What Would Justify Today's Price?
Narratives on Simply Wall St take that DCF puzzle for Ligand Pharmaceuticals and spell out which paths for growth, profitability and earnings would need to occur for the stock to appear materially undervalued or overvalued relative to today’s price. Each scenario connects its numbers to a clear view on how revenue trends, margin levels and business risks might evolve, so you can revisit those assumptions as fresh information appears on the Community page.
Community views on Ligand Pharmaceuticals split between those who see a scaled royalty engine as underappreciated and those who think execution risk is creeping ahead of the price.
Bull case: 9% undervalued
"Expansion of Ligand Pharmaceuticals’ high margin royalty portfolio through the completed XOMA Royalty acquisition, which adds more than 120 assets including additional commercial products and late stage programs, is expected to widen the base of recurring royalty revenue…"
Discover why this Narrative puts Ligand Pharmaceuticals at 9% undervalued.
Bear case: 17% overvalued
"The shift to a pure royalty aggregation model with a much smaller internal cost base concentrates results in a relatively small set of high-contribution royalty streams…"
Explore why this Narrative puts Ligand Pharmaceuticals at 17% overvalued.
Ligand Pharmaceuticals’ valuation still hinges on who is steering the ship
Price and cash flow tell only part of the story for Ligand Pharmaceuticals, because the track record, incentives and pay structure of the people in charge can tilt the risk and reward in very different directions. See who runs Ligand Pharmaceuticals and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com